Overall market sentiment has been neutral on Pfizer Inc. (PFE) stock lately. PFE receives a Neutral rating from InvestorsObserver's Stock Sentiment Indicator.
What is Stock Sentiment?
Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score.
As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend.
Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish.
InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion.
For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.
What's Happening With PFE Stock Today?
Pfizer Inc. (PFE) stock is trading at $36.70 as of 9:41 AM on Friday, Sep 18, a decline of -$0.10, or -0.29% from the previous closing price of $36.80. The stock has traded between $36.65 and $36.88 so far today. Volume today is light. So far 96,250 shares have traded compared to average volume of 22,298,084 shares.
To screen for more stocks like Pfizer Inc. click here.
More About Pfizer Inc.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales over $50 billion. Pfizer also spends a leading amount on research and development, close to $8 billion annually. While Pfizer historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, neuroscience drug Lyrica, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor, representing over a fifth of total firm sales.
Click Here to get the full Stock Score Report on Pfizer Inc. (PFE) Stock.
